文献速递免疫规划

一项2期随机盲法剂量探索对照临床试验:评估24价肺炎球菌结合疫苗(VAX-24)在65岁及以上健康成人中的安全性、耐受性和免疫原性

A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
PubMed 文献 · Vaccine · 2024-07-17

在65岁及以上健康成人中开展的2期随机盲法剂量探索对照试验显示,VAX-24三个剂量组与PCV20的安全性特征相当,所有24个血清型均诱导了稳健的OPA和IgG免疫应答;VAX-24 2.2 mcg剂量的免疫应答平均与PCV20相似或更高,支持该剂量进入3期试验。

要点

  • VAX-24三个剂量组与PCV20在接种后6个月内的安全性特征相当。
  • VAX-24所有24个血清型均诱导了稳健的OPA和IgG免疫应答。
  • VAX-24 2.2 mcg剂量的免疫应答平均与PCV20相似或更高,支持进入3期试验。

核心结论

  • 在65岁及以上成人中,VAX-24接种后6个月内的安全性特征与PCV20相似,并对所有24个血清型诱导了稳健的OPA和IgG应答。
  • VAX-24 2.2 mcg剂量的免疫应答平均与PCV20相似或更高,本2期研究结果进一步支持该剂量用于3期试验。

研究设计与样本

  • 2期随机盲法剂量探索对照临床试验,健康成人年龄65岁或以上按1:1:1:1随机接受单次注射VAX-24三个剂量水平之一(1.1、2.2或2.2/4.4 mcg混合剂量)或Prevnar 20®(PCV20)。
  • 入组207名参与者,200名完成试验。
  • 主要结局指标为接种后7天内的征集性局部和全身事件、1个月内非征集性不良事件(AEs)、接种后6个月内的严重AEs、就医AEs或新发慢性病。
  • 接种前和接种后1个月测量血清型特异性调理吞噬活性(OPA)和免疫球蛋白G(IgG)。

主要发现

  • VAX-24三个剂量组与PCV20的安全性特征相当。
  • 所有24个血清型均观察到稳健的OPA和IgG免疫应答。
  • 平均而言,VAX-24 2.2 mcg剂量的免疫应答与PCV20相似或更高。

临床怎么用

  • 原文结论指出,本2期研究结果进一步支持VAX-24 2.2 mcg剂量用于3期试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite current polysaccharide and conjugate vaccine use, pneumococcal diseases remain prevalent in older adults. VAX-24 is a 24-valent pneumococcal conjugate vaccine (PCV) containing eCRM, a proprietary carrier protein with non-native amino acids (para-azidomethyl-L-phenylalanine) that undergo site-specific conjugation to pneumococcal polysaccharides that have been activated with a small-molecule linker (dibenzocyclooctyne). Site-specific conjugation utilizing click chemistry enables consistent exposure of T-cell epitopes, reduction in carrier protein to pneumococcal polysaccharide ratio, and enhances manufacturing process consistency to improve PCVs by increasing serotype coverage while minimizing carrier suppression. Healthy adults aged 65 or older were randomized in a 1:1:1:1 ratio to receive a single injection of VAX-24 at 1 of 3 dose levels (1.1, 2.2, or a mixed dose of 2.2 or 4.4 mcg) or Prevnar 20® (PCV20) in a phase 2, blinded study. Primary outcome measures were solicited local and systemic events within 7 days post-vaccination, unsolicited adverse events (AEs) within 1 month, and serious AEs, medically attended AEs, or new onset of chronic disease within 6 months of vaccination. Serotype-specific opsonophagocytic activity (OPA) and immunoglobulin G (IgG) were measured pre-vaccination and at 1 month post-vaccination. Of 207 participants enrolled, 200 completed the trial. Safety profiles were comparable across the three VAX-24 doses and PCV20. Robust OPA and IgG immune responses were seen for all 24 serotypes. On average, immune responses to VAX-24 2.2 mcg dose were similar or higher compared to PCV20. In adults ≥ 65 years, VAX-24 had a safety profile similar to PCV20 through six months post-vaccination and induced robust OPA and IgG responses to all 24 serotypes, supporting prior data showing that site-specific conjugation allows for increased serotype coverage with similar or higher immune response vs other PCVs. The outcome of this phase 2 study further supports use of VAX-24 2.2 mcg dose in phase 3 trials. Clinicaltrials.gov: NCT05297578.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wassil J, Sisti M, Fairman J, et al. A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older. Vaccine. 2024. PMID: 39025698. doi:10.1016/j.vaccine.2024.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。